Detalhe da pesquisa
1.
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial).
Ann Oncol
; 34(6): 520-530, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36863483
2.
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.
Ann Oncol
; 34(3): 251-261, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535566
3.
Telemedicine acceptance by older adults in Hong Kong during a hypothetical severe outbreak and after the COVID-19 pandemic: a cross-sectional cohort survey.
Hong Kong Med J
; 29(5): 412-420, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794613
4.
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.
Ann Oncol
; 30(1): 57-67, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30462163
5.
How liquid biopsies can change clinical practice in oncology.
Ann Oncol
; 30(10): 1580-1590, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31373349
6.
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Ann Oncol
; 30(7): 1134-1142, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30918950
7.
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Gynecol Oncol
; 153(2): 304-311, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30792002
8.
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Ann Oncol
; 29(11): 2175-2182, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30202892
9.
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.
Ann Oncol
; 29(1): 30-35, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29140430
10.
Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.
Br J Cancer
; 117(12): 1743-1752, 2017 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29065104
11.
Data resources for the identification and interpretation of actionable mutations by clinicians.
Ann Oncol
; 28(5): 946-957, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327901
12.
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Ann Oncol
; 28(10): 2377-2385, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945858
13.
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape.
Ann Oncol
; 28(5): 1145-1151, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28453708
14.
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Gynecol Oncol
; 144(2): 250-255, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28062115
15.
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
Br J Cancer
; 112(4): 650-9, 2015 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25625276
16.
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Br J Cancer
; 113(11): 1534-40, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26554651
17.
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.
Ann Oncol
; 26(9): 1824-1829, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25888611
18.
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
Br J Cancer
; 111(12): 2262-7, 2014 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25393368
19.
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
Br J Cancer
; 111(10): 1932-44, 2014 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25290091
20.
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
Br J Cancer
; 110(3): 648-55, 2014 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335920